Wire · opportunities
Tonix Gets FDA Alignment on TNX-4800 Phase 2 Lyme Disease Study Design
◆ Sectors
Biotech
◆ Geography
United States
◆ Source
◆ Verified
Fusion42 · 5 August 2026 · Fusion42 review
Tonix Pharmaceuticals received FDA alignment on the design of its Phase 2 clinical trial for TNX-4800, a long-acting monoclonal antibody for Lyme disease prevention, clearing a major regulatory uncertainty and enabling protocol finalisation.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
Your Lyme disease treatment can now move past regulatory guesswork, opening a clearer path to trial execution and data collection this year. This shift demands close attention to patient enrolment rates in 2028 to avoid timeline delays.
◆ Coverage
1 source · 5 Aug 2026
◆ Related on Wire
◆ Topics
Biotechfda-alignmentlyme-diseasephase-2-trialmonoclonal-antibodyclinical-development